Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma.

Trial Profile

Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2015

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Sep 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 24 Dec 2012 NCT report Actual Number of Patients 70.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top